JK 06
Alternative Names: JK-06Latest Information Update: 20 Jun 2025
At a glance
- Originator SalubrisBio
- Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoprotein stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics, adverse events and pharmacokinetics data from preclinical studies in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 23 Dec 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Spain, Belgium (IV) (NCT06667960)
- 06 Aug 2024 Salubris Biotherapeutics received approval from the European Medicines Agency (EMA) for JK06